Navigation Links
GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
Date:9/9/2009

NEW YORK, Sept. 9 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

The Company is aggressively acquiring patents involving the latest generation of biotherapeutic technologies that can cure cancer without any side effects.

With a focus on prostate and breast cancers, GENova has acquired a unique class of drugs that utilize stem cell technology to identify, target, and destroy the very originator stem cells that give rise to cancers. These bio-engineered drugs can seek out cancers right at the source, and destroy them whilst leaving healthy tissues intact.

The Company has already filed patents for these drug targets, and has identified similar ones for acquisition. Researchers in academic labs have expressed confidence that this novel approach to treating cancer is the way of the future, and will render current painful treatments obsolete.

John Savin, VP for GENova, explained the Company's unique strategy for penetrating the lucrative drug development industry: "We occupy a strategic point in the drug development and supply chain, as the intermediary between research institutions and the Big Pharmaceutical companies. Our strategy is one of global outsourcing, international collaboration, using the FDA fast track to accelerate drug development, and then early exit to cash-rich and technology-hungry Big Pharma."

Savin said that if GENova's current IP is developed successfully, he estimates that the Company could expect up to $100 Million in milestone payments during clinical trials, and up to $400 Million per annum in the years following commercialization. His estimates are based on evaluations of other successful drug targets in the industry.

Big Pharma presently has $215 Billion to spend on licensing of new drugs, and is eager to feed the
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
2. Genova files patent for new prostate cancer treatment
3. GENova names Dr. John Savin as Vice President
4. GENova names Aaron Whiteman as CEO
5. Karmanos Chief Cancer Surveillance Researcher Discusses Study on Decreased Cancer Mortality Rates
6. Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates
7. The Caryl Ehrlich Program Discusses Food Addiction on HealthyPlace.com
8. Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States
9. Natural Healers Discusses How Alternative Medicine Careers Provide a Little 'Wellness' in a Tough Economy
10. Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview
11. All Nursing Schools Discusses Obama's Health Care Reform and Nursing Career Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Chertok now provides gum disease patients with a new alternative ... of a healthier smile. Laser gum surgery or ... diseased gum tissue in patients, but it also stimulates bone ... , LANAP uses a laser to successfully treat and ... healthy tissue as well as encourage new bone growth. With ...
(Date:5/19/2013)... Yeast infections are common in both men and women. These ... body. A new yeast infection treatment product has been released ... of application to help eliminate over growth of the candida ... and women searching for a natural process of yeast elimination. ... and is stored in the intestines. In small consumable doses, ...
(Date:5/19/2013)... 19, 2013 Passages Malibu, the leading ... has announced this week the launch of a “Sobriety, ... social media channels. “We are always looking for ... and to get feedback regarding sobriety, what’s working for ... co-founder of the Passages Addiction Treatment Centers ...
(Date:5/19/2013)... The AMTC team will be screening local Columbus talent at ... Center on June 1st. Professionals and amateurs, ages 4 and ... charge. , Actors, Models and Talent for Christ (AMTC) has ... grads like Caitlin Kinney - SYTYCD, Caleb Callahan - ... on his Liquid Neon 2013 Tour, Taylor Beckham - The ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 The legal ... website YazSideEffects.com in a concerted effort to connect women ... combination birth control drugs Yaz, Yasmin & Ocella with ... wealth of information on the notorious birth control drugs ... Bayer Pharmaceuticals. , Yaz, Yasmin & Ocella were ...
Breaking Medicine News(10 mins):Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... (June 10, 2008) The Endocrine Society ... investigator at Los Angeles Biomedical Research Institute at ... Educator Award during its annual convention June 15-18 ... international association of 13,000 members representing the full ...
... 2008) Screening for lung cancer with computed tomography (CT) ... smokers, but it won,t protect them from other causes of ... in the July issue of the journal Radiology . ... way to reduce risk of death from lung cancer," said ...
... Middle- and upper-income families find it harder to get needed ... -- The number of American adults who had inadequate health ... 2003 to 2007, from 16 million to more than 25 ... higher incomes, those whose income was 200 percent above the ...
... That Include,Avastin, Erbitux, Rituxan/MabThera, According to a New Report from Decision ... ... Mass., June 10 Decision Resources, one of the,world,s leading research ... antibodies (MAbs) drug market,will more than double to $16.7 billion in ...
... SCOTTSDALE, Ariz., June 10 Examination Management,Services, ... retrieval services,in the nation, and Cybersettle, the ... to provide Cybersettle users with integrated,medical record ... of,claim disputes., Combining Cybersettle,s Web-based dispute ...
... Announce Plans for Celebrating World Blood Donor,Day on ... To increase national,and global appreciation of volunteer blood ... (ADRP) are partnering together to,encourage their respective members ... 14. This specific day marks the birthday of ...
Cached Medicine News:Health News:LA BioMed investigator wins Distinguished Educator Award 2Health News:CT lung cancer screening no cure-all for smokers 2Health News:25 Million Americans Are 'Underinsured' 2Health News:25 Million Americans Are 'Underinsured' 3Health News:25 Million Americans Are 'Underinsured' 4Health News:The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016 2Health News:EMSI and Cybersettle Partner to Provide Cybersettle Clients With Medical Record Retrieval Services 2Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 2Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 3Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 4
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- The escalation of new ... placing renewed emphasis on alternate delivery technologies. Alternate ... number of factors are converging to create both ... their delivery device partners . These include new ... growing trend toward self-administration for chronic diseases, shifting ...
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... N.J. , May 17, 2013  PENTAX ... and Hitachi-Aloka Medical, a global leader in ultrasound ... two global companies to enable further innovation in ... years, the Hitachi-Aloka ultrasound systems and PENTAX Medical ... most trusted families of EUS systems. This agreement ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... Effective in Patients ... Surgery, WASHINGTON, Sept. 1 Data announced today ... complex coronary,artery disease can safely choose to be treated ... The Society for,Cardiovascular Angiography and Interventions (SCAI). The one-year ...
... MUNICH, Germany, September 1 Biosensors,International Group, ... that a next-generation drug-eluting stent,developed by Biosensors, ... to Johnson & Johnson,s industry leading drug-eluting ... and angiographic,follow-up data. The results of the ...
Cached Medicine Technology:SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 2Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 3
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
... provides hospitals and alternate care facilities ... care trays which offer the finest ... Designed with the guidance of experienced ... provide exactly what is required for ...
... Kendall provides hospitals and alternate ... of tracheostomy care trays which offer ... infection control. Designed with the guidance ... total-care trays provide exactly what is ...
For use with cushioned neckband....
Medicine Products: